Basilea’s partner Asahi Kasei Pharma completes patient enrolment in phase 3 study with antifungal isavuconazole (Cresemba®) in Japan

7. Januar 2021 INDIZES USA

Basilea’s partner Asahi Kasei Pharma completes patient enrolment in phase 3 study with antifungal isavuconazole (Cresemba®) in Japan …
(Orginal – Story lesen…)

Tags: dow jones nasdaq s&p 500

You may also like...